The private biotech sector is awash in capital today, up over 250% in the past few years. The author explores whether private CEO cash compensation has also risen with the increase in funding, and reviews compensation benchmarking best practices.
from Forbes Real Time https://www.forbes.com/sites/brucebooth/2018/06/01/biotech-ceo-pay-inflation-held-at-bay/
via IFTTT
No comments:
Post a Comment